ADAGENE INC. SP.ADR (978) - Total Liabilities
Based on the latest financial reports, ADAGENE INC. SP.ADR (978) has total liabilities worth €42.91 Million EUR (≈ $50.17 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of ADAGENE INC. SP.ADR to track the company's year-over-year net asset growth rate.
ADAGENE INC. SP.ADR - Total Liabilities Trend (2021–2025)
This chart illustrates how ADAGENE INC. SP.ADR's total liabilities have evolved over time, based on quarterly financial data.
ADAGENE INC. SP.ADR Competitors by Total Liabilities
The table below lists competitors of ADAGENE INC. SP.ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shenzhen Jianyi Decoration Group Co Ltd
SHE:002789
|
China | CN¥9.81 Billion |
|
Solar A/S
CO:SOLAR-B
|
Denmark | Dkr4.30 Billion |
|
Backblaze Inc
NASDAQ:BLZE
|
USA | $108.70 Million |
|
Northern Ocean Ltd
OL:NOL
|
Norway | Nkr662.45 Million |
|
Coincheck Group N.V. Ordinary Shares
NASDAQ:CNCK
|
USA | $113.97 Billion |
|
Goody Science & Technology Co Ltd
SHE:002694
|
China | CN¥1.12 Billion |
|
Zwack Unicum Likoripari es Kereskedelmi Nyrt.
BUD:ZWACK
|
Hungary | Ft9.95 Billion |
|
GNCO Co. Ltd
KQ:065060
|
Korea | ₩122.63 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down ADAGENE INC. SP.ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 978 market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ADAGENE INC. SP.ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ADAGENE INC. SP.ADR (2021–2025)
The table below shows the annual total liabilities of ADAGENE INC. SP.ADR from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €42.91 Million ≈ $50.17 Million |
+10.76% |
| 2024-12-31 | €38.74 Million ≈ $45.30 Million |
-14.22% |
| 2023-12-31 | €45.17 Million ≈ $52.81 Million |
-34.83% |
| 2022-12-31 | €69.31 Million ≈ $81.03 Million |
+110.33% |
| 2021-12-31 | €32.95 Million ≈ $38.52 Million |
-- |
About ADAGENE INC. SP.ADR
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 anti… Read more